Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 4 institutions in 4 countries.
Alessia CaputoLaboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy.ORCID 0000-0002-6219-4096
Sara SartiniLaboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy.
Elisabetta LevatiLaboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy.ORCID 0000-0001-8125-638X
Ilaria MinatoLaboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy.
Gian Marco ElisiDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID 0000-0001-9071-5621
Adriana Di StasiDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Catherine GuillouCentre de Recherche de Gif, Institut de Chimie des Substances Naturelles, CNRS, 1 Avenue de la Terrasse, 91198 Gif-sur-Yvette, France.ORCID 0000-0003-0693-0703
Peter G GoekjianLaboratoire Chimie Organique 2 Glycochimie, ICBMS UMR 5246 CNRS-Université Claude Bernard Lyon 1, Université de Lyon, 69622 Villeurbanne, France.
Pierre GarciaLaboratoire Chimie Organique 2 Glycochimie, ICBMS UMR 5246 CNRS-Université Claude Bernard Lyon 1, Université de Lyon, 69622 Villeurbanne, France.
David GueyrardLaboratoire Chimie Organique 2 Glycochimie, ICBMS UMR 5246 CNRS-Université Claude Bernard Lyon 1, Université de Lyon, 69622 Villeurbanne, France.ORCID 0000-0002-9657-3836
Stéphane BachSorbonne Université, CNRS, UMR 8227, Integrative Biology of Marine Models, Team Physiology and Cell Fate, Station Biologique de Roscoff, CS 90074, 29680 Roscoff, France.ORCID 0000-0002-7186-7483
Arnaud ComteChimiothèque, ICBMS UMR 5246 CNRS-Université Claude Bernard Lyon 1, Université de Lyon, 69622 Villeurbanne, France.ORCID 0000-0001-8835-0483
Simone OttonelloLaboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy.
Silvia RivaraInterdepartmental Research Centre Biopharmanet-Tec, University of Parma, 43124 Parma, Italy.ORCID 0000-0001-8058-4250
Barbara MontaniniLaboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy.ORCID 0000-0002-5419-7975
University of Parma · ITUniversité Claude Bernard Lyon 1 · FRCentre National de la Recherche Scientifique · FRUniversity of Trieste · IT
Funding
Italian Ministry of Education, University and Research Progetti Competitivi MUR ex DM 1059/2021University of Parma, Italy Bando Straordinario 591 di Ateneo per Progetti di Ricerca Biomedica in Ambito SARS-COV-2 e COVID-19- 2020
6 · The paper itself
Abstract
Bacterial resistance represents a major health problem worldwide and there is an urgent need to develop first-in-class compounds directed against new therapeutic targets. We previously developed a drug-discovery platform to identify new antimicrobials able to disrupt the protein-protein interaction between the β' subunit and the σ
Indexed as
antibioticsbacterial RNA polymerase (RNAP)bacterial transcription inhibitorsdrug-discovery workflowprotein–protein interaction inhibitorprotein–protein interaction (PPI)RNAP holoenzyme assemblyyeast Bioluminescence Resonance Energy Transfer (yBRET)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
An Optimized Workflow for the Discovery of New Antimicrobial Compounds Targeting Bacterial RNA Polymerase Complex Formation. · full record | OpenQuestion